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Cardiovascular disease (CVD) is the leading cause of death in women older than 50 years. Risk factors for CVD differ in some 
aspects from those in men. The prevention of CVD in women has undergone a reappraisal with the publication of studies looking 
at the use of menopausal hormone therapy for both primary and secondary prevention. Although these studies concluded that 
there was no place for the use of hormone therapy for prevention of CVD, recent data suggests that the issue is still not resolved 
as regards the younger woman in early menopause. Until more data is available in this regard, the main focus of prevention 
should be on interventions to decrease risk factors for cardiovascular disease.        
Introduction
Cardiovascular disease (CVD) includes 
hypertension, coronary heart disease 
(CHD), atherosclerosis and stroke. It is 
the leading cause of death in women 
who are more than 50 years of age in 
Western countries.1 CVD accounts for 
53% of female deaths. Using the fig-
ures supplied by the American Heart 
Association, in the year 2003, 484,000 
women died of CVD the USA.2 This is 
approximately 57,000 more than the 
number of men who died of the same 
condition. Whereas death rates in men 
from CVD have shown a progressive de-
crease since 1980, death rates in wom-
en from this condition have remained 
constant. In spite of this, both patients 
and health care providers continue to 
underestimate the extent of this problem 
in women, where the focus is more on 
breast cancer, and health care provid-
ers still considering this predominantly a 
disease in men. 
Prior to menopause, the incidence 
of CVD in women is lower than seen 
in men.2 Incidence becomes similar in 
men and women between 45 and 55 
years of age. Thereafter more women 
have CVD than do men.
Risk factors of CVD in women
1. Menopause 
The onset of menopause at any age ear-
lier than 55 years results in an increase 
in the incidence of CVD. As an example, 
in the Framingham study, in a sample 
of 2873 women, in all age groups the 
incidence of CHD was lower in pre-
menopausal than in postmenopausal 
women.3 This was especially marked 
in the 40 - 44 year group but even in 
the 45 - 49 and 50 - 54 year groups the 
incidence in postmenopausal women 
was double that seen in premenopausal 
women.
 2. Dyslipidaemia
The onset of menopause results in an 
unfavourable shift in lipid levels. Total 
cholesterol, low density lipoprotein 
cholesterol (LDL), and triglycerides 
(TG) increase while a decrease is seen 
in high density lipoprotein cholesterol 
(HDL) and HDL2 cholesterol. This effect 
is independent of age, body mass index 
(BMI) and other confounding variables.4 
Women, however, differ from men as 
to the significance of these abnormal 
lipoproteins. In both men and women, 
CHD is increased with increasing LDL 
and total cholesterol levels. Hyper-
triglyceridaemia is, however, a more 
potent independent risk factor for CHD 
in women compared to men.5 A meta-
analysis of 17 studies (n = 46,413 men 
and 10,864 women) revealed that the 
CHD relative risk (RR) for hypertriglyc-
eridaemia was elevated by 32% in men 
and 76% in women.6 Low HDL is more 
predictive of coronary heart disease risk 
in older women than it is in men.7 
3. Hypertension
Hypertension is an important risk fac-
tor for CVD in men and women. With 
Wong et al,  based on an analysis of the 
NHANES data, calculated showed that 
control of hypertension to high normal 
levels would prevent approximately 20% 
of CHD events in men and 33% of CHD 
events in women.8 If there was control 
to optimum levels, this would increase to 
37% and 56% respectively. If hyperten-
sion, LDL cholesterol and HDL choles-
terol were controlled to optimum levels, 
the same investigators showed that 
82.1% of CHD events in women could 
be prevented.9 A meta-analysis of data 
for 1 million men and women showed 
that for every 20 mm Hg difference in 
systolic blood pressure there is a 2 X 
difference in death rates due to stroke.10 
This is true in men and women.   
4. Diabetes
It has been reported that diabetic wom-
en have a significantly higher cardiovas-
cular mortality than diabetic men.11 The 
relative risk of a fatal ischaemic heart 
event was 3.3 in diabetic vs non diabetic 
women and 1.8 in diabetic vs non-dia-
betic men. A similar difference has been 
reported by Hu et al who reported the 
relative risk for cardiovascular mortality 
in women with type II diabetes to be 4.4 
as opposed to 2.2 in men.12
5. Obesity 
Numerous population studies have 
shown an increased risk for CVD in 
overweight or obese men and women. 
In a Dutch prospective cohort study, it 
was estimated that 28% of CHD mortal-
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ity could be attributed to being over-
weight (BMI > or = 25 kg/m2).13 In a 20 
year follow-up of 15,402 obese men and 
women in Scotland, it was estimated 
that obesity in women was associated 
with 7 extra cardiovascular deaths and 
28 extra cardiovascular admissions per 
100 affected individuals.14
 
6. The Metabolic Syndrome
The metabolic syndrome is a clustering 
of risk conditions including dyslipidae-
mia (elevated TG, decreased HDL cho-
lesterol), hypertension and abdominal 
obesity. Diagnosis in women requires 
the presence of 3 or more of the fol-
lowing: 
1. Waist circumference > 88 cms) 
2.  Fasting TG ≥ 1.7 mmol/l 
 (150 mg/dl) 
3.  HDL cholesterol < 1.1 mmol/l 
 (50 mg/dl) 
4.  Hypertension (systolic blood pres-
sure ≥ 130 mm Hg, diastolic blood 
pressure ≥ 85 mmHg, or use of anti-
hypertensive drug  therapy)
5.  A fasting glucose measurement >or 
= 5.6mmol/l (100mg/dl).15 Postmeno-
pausal status is associated with a 
60% increased risk of metabolic syn-
drome, even after adjusting for vari-
ables such as age, BMI or physical 
inactivity.16 The metabolic syndrome 
appears to carry an especially high 
risk of CVD in women and it has been 
estimated that half of all cardiovascu-
lar events in women are related to this 
syndrome17 
6. Smoking
For women smokers, CHD mortality risk 
from cigarettes is equivalent to the risk 
associated with weighing 42 kg more 
than her non smoking counterpart.18 
The role of estrogen in the prevention 
of cardiovascular disease
The increase in the incidence of cardio-
vascular disease with onset of meno-
pause at any age suggests a protective 
effect of estrogen on the vasculature. 
This is biologically plausible given the 
effect of estrogen on many surrogate 
markers of CVD. Oral estrogen, given 
alone or in combination with a progestin, 
improves lipoprotein profiles and low-
ers fibrinogen levels.19 Both oral and 
transdermal estrogen improve glucose 
metabolism, have a beneficial effect on 
the vascular endothelium and reduce 
homocysteine levels. Other beneficial 
effects include a reduction of lipoprotein 
(a) levels.20 The addition of a progestin 
partly attenuates the beneficial effect 
on lipoproteins. This effect varies ac-
cording to the dose and androgenicity 
of the progestin.  However, not all of the 
effects of estrogen are beneficial.  Oral 
estrogen increases triglyceride levels. 
Oral estrogen also increases levels 
of C-reactive protein, an inflammatory 
marker that may independently increase 
the risk of heart disease. 21 This increase 
is not apparent with transdermal hor-
mone therapy. The production of matrix 
metalloproteinases are increased by 
oral estrogen.22 These are degradative 
enzymes that are important in destabili-
sation and rupture of plaque.
Observational studies have suggest-
ed that menopausal hormone therapy 
may prevent CHD. The most compelling 
is the Nurses Health Study (NHS), a 20 
year prospective observational study. 
Among 70,533 participants with no his-
tory of cardiovascular disease, current 
use of HT, as compared with it never 
having been used was associated with 
RR of 0.61 (95% CI, 0.52 - 0.71) for a 
major cardiac event.23 In the Rancho 
Bernado study, in a cohort of 204 post-
menopausal women, current estrogen 
users had a 60% decreased risk of 
severe coronary artery disease (RR 0.40 
[95% CI 0.19 - 0.82]).24 
The suggested benefit of estrogen 
therapy on cardiovascular mortality has, 
however, not been confirmed by pro-
spective randomised controlled trials. 
The Heart and Estrogen/Progestin Re-
placement Study (HERS), a secondary 
prevention study, compared the effect 
of conjugated equine estrogen (CEE) 
combined with medroxyprogesterone 
acetate (MPA), with placebo. It showed 
no reduction in the incidence of any 
cardiovascular outcomes over 4.1 years 
in those patients using CEE and MPA.25 
In the first year of this study, there was 
a 50% higher risk of non-fatal myocar-
dial infarction in the group receiving HT. 
There was a decreased risk in years 3 
to 5. This lower rate did not, however, 
persist during a 2.7 year follow-up of the 
HERS patients leading to the conclusion 
that postmenopausal hormone therapy 
should not be used to reduce the risk of 
CHD events in women with CHD.26 This 
is consistent with other studies on sec-
ondary prevention and has been shown 
with both CEE and 17ß estradiol.27, 28 
There was also no protective effect in a 
secondary prevention study using trans-
dermal estrogen.29 
The Women’s Heath Initiative (WHI) 
study was designed to address the is-
sue of primary prevention. There were 
two parallel arms in a study on more 
than 26,000 women.30, 31 The CEE plus 
progestin part of the study was stopped 
after 5.2 years because of risks out-
weighing benefits. At that stage there 
was an overall 24% increase in the in-
cidence of CHD (nominal 95% CI 1.00 
- 1.54).32 As in the HERS study, this was 
most apparent at 1 year (RR 1.81 [95% 
CI 1.09 - 3.01]) with a trend toward a 
decreasing risk thereafter. The estrogen 
only arm of the WHI study also ended 
early (6.8 years) and again did not show 
any decrease in cardiovascular risk (RR 
0.95 [95% CI 0.79 - 1.16]). Unlike the 
combined arm, there was no increase 
in risk in year 1 (RR 1.11 [95% CI 0.64 
- 1.94]) and no significant trend with 
time. 
Stroke risk with hormone use was 
increased and similar in both arms of 
the WHI study. The RR for stroke in the 
estrogen plus progestin arm was 1.31 
(95% CI 1.02 - 1.68) and in the estrogen 
only arm 1.37 (95% CI 1.09 - 1.73). 
The difference between the re-
sults of observational studies and the 
randomised controlled studies has 
attracted much comment. Manson 
provides an insightful overview of these 
issues.33 Observational studies may be 
biased due to a “healthy user effect”, 
i.e. women who choose to take HT tend 
to be healthier and tend to adopt other 
health promoting interventions. If this 
was the situation for the WHI studies 
it is therefore strange that, with other 
endpoints of this study such as venous 
thrombosis, stroke and breast cancer, 
the results were in accordance with the 
observational studies. Observational 
studies can also be compromised be-
cause, due to infrequent capture of 
adverse events, early clinical events 
may be misinterpreted as occurring in 
a non-user or in a non-using interval. 
This could be especially important in 
studies on CHD outcomes where, as 
shown in WHI and HERS, most events 
occur early in the study. An extremely 
important difference is, however, the dif-
ference in the clinical characteristics of 
the study populations. In observational 
studies such as the NHS study, the ma-
jority of the participants started hormone 
therapy (HT) early in the menopause. 
This is not the case in WHI and HERS 
studies where the mean baseline ages 
were 63 and 67 years respectively. At 
this older age, the majority of women 
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would be expected to have a degree of 
atherosclerosis. This obvious difference 
has lead to a “window of opportunity” 
hypothesis where HT may be of benefit 
in the younger patient with healthy vas-
culature, whereas, in the older patient, 
initiating HT for the first time, where vas-
cular damage has already occurred, HT 
would be detrimental. The results as re-
gards the incidence of CVD in the estro-
gen only arm of the WHI lends support 
to this hypothesis.34 When looking at the 
primary outcome of myocardial infarc-
tion (MI) and coronary death, the risk for 
developing one of these events with use 
of estrogen therapy increased with age. 
In the age groups 50 - 59 years, 60 - 69 
years and 70 -79 years, the RR’s were 
0.61 (95% CI, 0.25 - 1.50), 0.86 (95% 
CI, 0.60 - 1.25), and 1.10 (95% CI, 0.69 
- 1.73). As regards the composite out-
come of MI, coronary death, coronary 
revascularisation and angina, there 
was a significant reduction with use of 
estrogen in the 50 - 59 year age group 
(RR 0.66 [95% CI, 0.45 - 0.96]). There 
was no difference in composite out-
comes in the 60 - 69 or 70 - 79 year age 
groups. A re-analysis of the NHS data 
looking at age again shows benefit with 
initiating HT early in menopause with no 
benefit in women starting HT at a later 
stage.35 Where HT was initiated near 
menopause, the RR of CHD for estrogen 
use alone was 0.66 (95% CI, 0.54 - 0.92) 
and for estrogen/progestin use was 
0.72 (95% CI, 0.56 - 0.92). Where HT 
was initiated more than 10 years after 
menopause, the RR for estrogen and 
estrogen/progestin use were 0.87 (95% 
CI, 0.69 - 1.10) and 0.90 (95% CI, 0.62 
- 1.29) respectively. 
Nonhuman primate studies also sup-
port the window of opportunity hypoth-
esis. Where CEE, with or without MPA, 
was started in cynomolgus monkeys 
immediately after oophorectomy, there 
was a reduction in the extent of plaque 
formation due to atherosclerosis.36 If the 
HT was delayed by 2 years, which is 
equivalent to 6 human years, there was 
no effect on plaque development. 
The debate about the role of HT in 
the prevention of CVD in postmeno-
pausal women will continue until there 
are prospective randomised controlled 
studies that address this issue in re-
cently menopausal women. The Kronos 
Early Prevention Study (KEEPS) is one of 
these studies.37 It may also shed light on 
the issue as to whether there is a differ-
ence between oral or transdermal estro-
gen as regards cardiovascular disease. 
Until we have Level I evidence that HT 
protects menopausal women against 
CVD it should not be prescribed where 
this is the only indication.        
The prevention of heart disease in 
women should, therefore, be based on 
proven interventions. At present there 
is no evidence for the efficacy of aspirin 
in the prevention of myocardial infarc-
tion or cardiovascular death in women. 
The Women’s Health Study, a 10 year 
prospective study of 39,876 healthy 
women aged 45 years or older, showed 
the  relative risk for major cardiovascular 
events  with aspirin use to be 0.91 (95% 
CI, 0.80 - 1.03).38 Ischaemic strokes 
were, however, significantly decreased 
(RR 0.76 [95% CI, 0.63 - 0.93]). A recent 
meta-analysis confirmed that statins 
have proven benefit in decreasing CHD 
mortality in patients with coronary heart 
disease.39  The issue as regards primary 
prevention in women is not as clear. In 
the same meta-analysis, although CHD 
events were decreased, there was no 
decrease in CHD or total mortality in 
patients without CHD. However, current 
guidelines for cardiovascular disease 
prevention emphasise the importance 
of achieving recommended lipoprotein 
goals.40      
As discussed under risk factors for 
CVD in women, there is evidence for 
cardiovascular compromise caused by 
dyslipidaemias, hypertension, diabe-
tes, obesity, the metabolic syndrome 
and smoking. Treatments and lifestyle 
interventions to address these prob-
lems should form an integral part of 
prevention programmes in menopausal 
women. Considering the morbidity and 
mortality of cardiovascular events, a 
paradigm shift away from the hot flush 
discussion, PAP smear and breast ex-
amination focus of the “regular check” in 
menopausal women, towards a disease 
prevention strategy with focus on other 
risk factors such as those for cardiovas-
cular disease, would have far reaching 
health benefits for women.  
See CPD Questionnaire, page 41
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Short course on Palliative Care 
in Family Medicine
Stellenbosch University, Division of 
Family Medicine and Primary Care 
will be offering a 12-week short 
course on palliative care via the 
Internet from 20th August to 12th 
November 2007. The course is reg-
istered for CEU points.
The course will cover the principles 
of palliative care, common psycho-
social issues and symptom manage-
ment. 
If you are interested in joining the 
course please contact Ms Han-
nilie Griggs on 021 938 9061 or 
jagr@sun.ac.za
